Sexual health

Mycoplasma Genitalium, the STI You Haven't Heard Of

Save

It has no household name, no awareness ribbon, and no place on the standard STI panel — yet Mycoplasma genitalium is a real, common infection that behaves a lot like chlamydia and resists antibiotics more easily. Here is what the bacterium is, how it spreads, why testing is not routine, and why treating it has become one of the harder problems in sexual health.

Last updated: July 2026History

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

What Mycoplasma genitalium is

Mycoplasma genitalium is a bacterium — one of the smallest known — that is passed through sexual contact and infects the urethra in men and the cervix in women, the same tissues chlamydia and gonorrhea affect. It was first identified in the early 1980s and only more recently confirmed as a genuine sexually transmitted infection, which is part of why it is so much less familiar than the STIs it resembles 1.

In practical terms, M. genitalium is a common cause of the inflammation clinicians call nongonococcal urethritis in men and cervicitis in women — irritation of the urethra or cervix that is not due to gonorrhea. It is included in the CDC's national STI treatment guidelines, but it sits in an unusual position: recognized as a real pathogen, yet not screened for the way chlamydia and gonorrhea are 2.

Most people who carry it have no idea, because, like the infections it mimics, it is frequently silent. What sets it apart is not how it presents but how it responds to treatment — it has a stronger tendency to resist the antibiotics used against it, which is the thread that runs through everything else worth knowing about it.

Why almost no one has heard of it

Mycoplasma genitalium flies under the radar for a few concrete reasons, none of which mean it is rare. It is not one of the STIs reported to and tracked by national surveillance — the three the U.S. counts nationally are chlamydia, gonorrhea, and syphilis, which together topped 2.4 million reported cases in 2023 3. Because M. genitalium is not on that list, there is no headline number for it and no annual report driving public awareness.

It is also genuinely hard to detect. The bacterium is slow and difficult to grow in a laboratory, so for decades there was no practical test at all; reliable molecular testing is comparatively new and still not available everywhere. And crucially, health authorities do not recommend screening people who feel well for it, the way they do for chlamydia 1.

M. genitalium is common but invisible — not tracked nationally, not routinely screened for, and easy to miss without a specific test. The result is an infection that is probably more widespread than most people assume, yet has almost no public profile. Estimates of how common it is vary, but researchers generally place it in the same broad range as chlamydia among some sexually active groups — hardly the obscure footnote its name suggests.

How you get it, and what it does

Mycoplasma genitalium is transmitted through vaginal and anal sex — genital contact that exchanges the bacterium between partners — much like other STIs that live on the genital mucous membranes. It is not caught from surfaces, towels, or casual contact. Because it is so often symptomless, it can be passed on by someone who has no idea they are carrying it 1.

When it does cause symptoms, they overlap almost entirely with chlamydia and gonorrhea, which is one reason it goes unrecognized. In men it can cause urethritis — irritation, discharge, or burning with urination — that persists or comes back after standard treatment. In women it can cause cervicitis, unusual discharge, or bleeding between periods or after sex, and it has been linked to pelvic inflammatory disease, though its role in fertility is still being studied 2.

Anyone trying to make sense of Mycoplasma genitalium symptoms will notice the same pattern that defines the infection: mild, nonspecific, often absent, and indistinguishable from the more familiar STIs without a test. The tell, when there is one, is often a urethritis or cervicitis that does not clear the way a straightforward chlamydia infection would — a hint that something more resistant is at work.

Why it is so hard to treat

The reason Mycoplasma genitalium matters out of proportion to its fame is treatment. The bacterium lacks a cell wall, so the antibiotics that work by attacking cell walls — the penicillin family — do nothing against it. That leaves a narrow set of options, and the most convenient of them, the macrolide azithromycin, has lost much of its power as resistance has spread 1.

Because of that, current guidance uses a two-step approach rather than a single pill. Treatment typically begins with one antibiotic to lower the bacterial load, followed by a second chosen according to whether the strain is resistant to macrolides — azithromycin when it is not, and a different class, moxifloxacin, when it is. Where testing can determine resistance up front, that result guides which second drug is used 1 2.

Most Mycoplasma genitalium infections can still be cured — it just often takes a more deliberate, tested approach than a single course. Understanding Mycoplasma genitalium treatment mostly means understanding why it is not one-and-done: the drug has to match the strain, a follow-up test to confirm the cure is often recommended, and skipping steps is how resistant infections persist. This is exactly why clinicians do not reach for M. genitalium testing casually — a positive result commits them to a careful regimen.

When it is tested for, and when it is not

Mycoplasma genitalium is deliberately not part of routine STI screening. Guidelines advise against testing people who have no symptoms and against including it in the initial workup for urethritis or cervicitis. Instead, testing is reserved mainly for symptoms that persist or recur after standard treatment for chlamydia and gonorrhea — the situation where an unrecognized M. genitalium infection is a likely explanation 1.

That restraint is intentional. Because resistance is common and the antibiotics are limited, finding and treating symptomless infections could accelerate resistance without a clear benefit — so the strategy is to test when it will change what happens next, not to cast a wide net. As a result, many general clinics and standard panels do not include it, and at-home STI test kits vary in whether they offer it at all; anyone specifically wanting it checked usually has to ask.

Testing itself is a molecular test on a urine sample or a swab, similar to chlamydia testing, though it is not offered everywhere. Because it is a distinct test with its own availability, it does not fit neatly into the usual STI window-period timelines, and the practical question is less about timing than about whether a clinic can run it. People sometimes also worry about privacy — for instance whether a test will surface on a parent's insurance statement — and in every U.S. state, minors can consent to STI testing and treatment on their own, though some set a minimum age 4.

Partners, prevention, and what a diagnosis means

A Mycoplasma genitalium diagnosis is not a cause for alarm, but it does call for the same partner-aware handling as other STIs. Because reinfection from an untreated partner is a real risk, current partners are generally evaluated and treated, and having sex is usually paused until treatment is finished and, when advised, a test has confirmed the infection cleared. That coordination matters more here than with easier infections, precisely because the treatment is more fragile 1.

Prevention follows the same logic as other STIs spread through genital contact: fewer untested exposures and prompt attention to lingering symptoms are the main levers. Notably, the newer bacterial-STI prevention tools do not fill this gap — the CDC's doxy-PEP recommendation, a single dose of doxycycline after sex, targets syphilis, chlamydia, and gonorrhea, not Mycoplasma genitalium 5. So M. genitalium is not something the current prevention playbook is designed around.

What a diagnosis actually means is usually straightforward: a common, treatable infection that happens to demand a more careful course than its better-known cousins. The stakes are not that it is dangerous in most cases, but that half-treating it breeds resistance — which is why the whole approach, from selective testing to matched antibiotics to confirming the cure, is built around getting it right the first time.

Common questions

More common than its low profile suggests. Because it is not tracked by national surveillance and not routinely screened for, there is no official case count, but researchers generally place it in a similar broad range to chlamydia among some sexually active groups. Most people who carry it have no symptoms, so it spreads quietly and is often only found when symptoms persist after other treatment.

Yes, most infections can be cured, but it often takes a more deliberate approach than a single course of antibiotics. Because the bacterium resists some common drugs, treatment usually pairs one antibiotic with a second matched to whether the strain is resistant, and a follow-up test may be advised to confirm it cleared. Skipping steps is how resistant infections persist, so completing the full regimen matters.

Guidelines deliberately leave it off routine panels. Because resistance is common and the antibiotics are limited, testing people without symptoms could speed up resistance without a clear benefit. So testing is reserved mainly for symptoms that persist or recur after treatment for chlamydia and gonorrhea. Many clinics and home kits do not include it, and someone who wants it checked usually has to ask specifically.

It can cause pelvic inflammatory disease in women, and infections that reach the upper reproductive tract carry a risk of scarring and fertility problems, as with chlamydia and gonorrhea. Its exact contribution to infertility is still being studied and is less established than for those infections. The practical takeaway is that symptoms that persist after standard treatment are worth investigating rather than ignoring.

It is passed through sexual contact — vaginal and anal sex that exchanges the bacterium between partners — and lives on the genital mucous membranes, much like chlamydia. It is not spread by toilet seats, towels, or casual contact. Because it so often causes no symptoms, it is frequently transmitted by someone who does not know they carry it, which is why lingering symptoms after treatment are a useful clue.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When Mycoplasma genitalium symptoms need care

  • —Urethral or vaginal symptoms that persist or return after a full course of antibiotics, which can signal a drug-resistant infection
  • —Pelvic pain with fever, or pain during sex, which can signal pelvic inflammatory disease
  • —Pain and swelling in one testicle

Severe pelvic or lower-abdominal pain with a high fever needs same-day evaluation, and an emergency room if it is severe, because an untreated pelvic infection can escalate quickly.

This article is health education, not medical advice, and does not replace a diagnosis or treatment plan from a clinician who knows your history. Testing and treatment decisions should be made with a licensed provider.

Did this answer your question?

References

  1. 1.Centers for Disease Control and Prevention (2021). Mycoplasma genitalium - STI Treatment Guidelines. CDC STI Treatment Guidelines, 2021. linkRoutine M. genitalium testing is not recommended for initial urethritis or cervicitis workup but is considered for persistent symptoms after treatment; treatment uses a first antibiotic followed by azithromycin when macrolide-sensitive or moxifloxacin when macrolide-resistant.
  2. 2.Workowski KA, Bachmann LH, Chan PA, et al. (Centers for Disease Control and Prevention) (2021). Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recommendations and Reports, Vol. 70, No. 4. doi:10.15585/mmwr.rr7004a1 ✓M. genitalium causes urethritis and cervicitis and has been associated with pelvic inflammatory disease; it is included in the CDC's comprehensive STI diagnostic and treatment recommendations.
  3. 3.Centers for Disease Control and Prevention (2025). National Overview of STIs in 2023. CDC STI Statistics (Sexually Transmitted Infections Surveillance, 2023). linkThe three STIs the U.S. reports nationally — chlamydia, gonorrhea, and syphilis — together exceeded 2.4 million reported cases in 2023.
  4. 4.Guttmacher Institute (2024). Minors' Access to STI Services. Guttmacher Institute, State Policy. link ✓All 50 states and DC allow minors to consent to STI testing and treatment on their own, some with a minimum age.
  5. 5.Bachmann LH, Barbee LA, Chan P, et al. (Centers for Disease Control and Prevention) (2024). CDC Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024. MMWR Recommendations and Reports, Vol. 73, No. 2. doi:10.15585/mmwr.rr7302a1 ✓The CDC's doxy-PEP recommendation, a dose of doxycycline taken after sex, targets syphilis, chlamydia, and gonorrhea in eligible people and does not include Mycoplasma genitalium.

5 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — citations link their sources. Editorial policy

← Back to the health library